Skip to main content

Clinical Biochemistry, Drug Delivery & Therapy

The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.

With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.

In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.

Team

Fernando Moreno Flores

Fernando Moreno Flores

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Gonzalo González Silva

Gonzalo González Silva

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria Fidel Lledò

Maria Fidel Lledò

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Sarai Garriga Edo

Sarai Garriga Edo

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Verónica Villagrasa Araya

Verónica Villagrasa Araya

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Alba Estela García Fernández

Alba Estela García Fernández

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Fernando Moreno Flores

Fernando Moreno Flores

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Gonzalo González Silva

Gonzalo González Silva

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria Fidel Lledò

Maria Fidel Lledò

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Sarai Garriga Edo

Sarai Garriga Edo

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Verónica Villagrasa Araya

Verónica Villagrasa Araya

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Alba Estela García Fernández

Alba Estela García Fernández

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Projects

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 31/10/2025

(HEPAST) - Estrategias de terapia genica para controlar la infeccion por los virus de la Hepatitis B y Delta basada en el estudio de las cuasiespecies virales por secuenciación masiva

IP: Francisco Rodríguez Frias
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 157300
Reference: PID2021-126447OB-I00
Duration: 01/09/2022 - 01/09/2025

Ministerio de Ciencia

Estudio de quasispecies por metagenómica en neuropatías asociadas a virus por secuenciación masiva de nueva generación.

IP: Josep Quer Sivila
Collaborators: Sergi Colomer Castell, Lluís Viladomiu Catà, Damir Garcia Cehic, Maria Piñana Moro, Pablo Gabriel Medina, Arnau Llauradó Gayete, Carolina Campos Martinez, Alejandra Gonzalez Sánchez
Funding agency: Instituto de Salud Carlos III
Funding: 292820
Reference: PI22/00258
Duration: 01/01/2023 - 31/12/2025

Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo.

IP: Joaquin Seras Franzoso
Collaborators: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI22/01301
Duration: 01/01/2023 - 31/12/2025

Publications

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers.

PMID: 37745192
Journal: JHEP Reports
Year: 2023
Reference: JHEP Rep. 2023 Jul 13;5(10):100842. doi: 10.1016/j.jhepr.2023.100842. eCollection 2023 Oct.
Impact factor:
Publication type: Paper in international publication
Authors: Berg, Thomas; Bes, Marta; Buti, Maria; Buti, Maria; Casillas, Rosario; Esteban, Rafael; Esteban, Rafael; Palom, Adriana; Pfefferkorn, Maria; Rando-Segura, Ariadna et al.
DOI: 10.1016/j.jhepr.2023.100842

Time-Tested Strategies in Modern Context: A Bibliometric Study of Chemotherapy's Continued Importance in Colorectal Cancer Treatment.

PMID: 37760489
Journal: Cancers
Year: 2023
Reference: Cancers (Basel). 2023 Sep 12;15(18):4520. doi: 10.3390/cancers15184520.
Impact factor:
Publication type: Paper in international publication
Authors: Clar-Marmaneu, Helena; Garcia-Fernandez, Alba Estela; Garcia-Fernandez, Francisco Javier et al.
DOI: 10.3390/cancers15184520

Impact of time of culture specimen collection on the recovery of Neisseria gonorrhoeae after a positive nucleic acid amplification test.

PMID: 37802652
Journal: SEXUALLY TRANSMITTED INFECTIONS
Year: 2023
Reference: Sex Transm Infect. 2023 Oct 6:sextrans-2023-055899. doi: 10.1136/sextrans-2023-055899.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Lopez, Patricia; Alvarez-Lopez, Patricia; Arando, Maider; Arando, Maider; Blanco-Grau, Albert; Curran, Adrian; Curran, Adrian; Descalzo, Vicente; El Ouazzani, Rachid; Garcia, Jorge Nestor et al.
DOI: 10.1136/sextrans-2023-055899

Solved the enigma of pediatric severe acute hepatitis of unknown origin?

PMID: 37808908
Journal: Frontiers in Cellular and Infection Microbiology
Year: 2023
Reference: Front Cell Infect Microbiol. 2023 Sep 21;13:1175996. doi: 10.3389/fcimb.2023.1175996. eCollection 2023.
Impact factor:
Publication type: Review in international publication
Authors: Quer, Josep; Rando-Segura, Ariadna; Rodriguez-Frias, Francisco et al.
DOI: 10.3389/fcimb.2023.1175996

Blog

News

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.